296 related articles for article (PubMed ID: 36656298)
1. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
[TBL] [Abstract][Full Text] [Related]
3. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
5. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
Argyriou AA; Dermitzakis EV; Xiromerisiou G; Vikelis M
Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548744
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
7. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
Front Neurol; 2021; 12():788159. PubMed ID: 35069416
[No Abstract] [Full Text] [Related]
8. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
9. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
[TBL] [Abstract][Full Text] [Related]
11. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
[TBL] [Abstract][Full Text] [Related]
12. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
Cohen F; Armand C; Lipton RB; Vollbracht S
Pain Med; 2021 Aug; 22(8):1857-1863. PubMed ID: 33693863
[TBL] [Abstract][Full Text] [Related]
14. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
[TBL] [Abstract][Full Text] [Related]
15. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
[TBL] [Abstract][Full Text] [Related]
16. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
[TBL] [Abstract][Full Text] [Related]
17. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
19. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
20. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
